LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

CorMedix Inc

Chiusa

SettoreSettore sanitario

11.23 0.54

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.83

Massimo

11.61

Metriche Chiave

By Trading Economics

Entrata

-816K

20M

Vendite

655K

40M

P/E

Media del settore

14.205

105.69

EPS

0.28

Margine di Profitto

49.898

Dipendenti

64

EBITDA

-297K

21M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+64.14% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-53M

868M

Apertura precedente

10.69

Chiusura precedente

11.23

Notizie sul Sentiment di mercato

By Acuity

29%

71%

71 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

CorMedix Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 nov 2025, 17:45 UTC

Utili
I principali Market Mover

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Utili
I principali Market Mover

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 nov 2025, 16:15 UTC

I principali Market Mover

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 nov 2025, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Discorsi di Mercato

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Utili
Acquisizioni, Fusioni, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Utili

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Discorsi di Mercato

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisizioni, Fusioni, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Discorsi di Mercato
Utili

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Discorsi di Mercato
Utili

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Discorsi di Mercato

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Discorsi di Mercato

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Discorsi di Mercato

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Discorsi di Mercato

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 nov 2025, 16:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov 2025, 16:28 UTC

Discorsi di Mercato

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 nov 2025, 15:59 UTC

Discorsi di Mercato

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 nov 2025, 15:06 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 nov 2025, 15:06 UTC

Discorsi di Mercato

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Confronto tra pari

Modifica del prezzo

CorMedix Inc Previsione

Obiettivo di Prezzo

By TipRanks

64.14% in crescita

Previsioni per 12 mesi

Media 18.4 USD  64.14%

Alto 22 USD

Basso 14 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CorMedix Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

7

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.2 / N/ASupporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

71 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat